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Few immigrant travelers have Plasmodium falciparum 
infections >2 months after leaving malaria-endemic areas. 
We conducted a case–control study to identify factors as-
sociated with prolonged P. falciparum infection in immigrant 
travelers. Results suggest that P. falciparum infection should 
be systematically suspected, even months after travel, 
especially in pregnant women and ﬁ  rst-arrival immigrants.
A
pproximately 100 countries endemic for malaria are 
visited by 125 million international travelers yearly, 
and >30,000 contract imported malaria (1). In France, the 
number of imported cases of Plasmodium falciparum ma-
laria was estimated to be 4,500 in 2004, with a median time 
of 10 days between departure from an area endemic for 
malaria and diagnosis (2). The duration of a P. falciparum 
infection in humans is generally believed not to exceed 12 
months. Most epidemiologic studies show that few patients 
have malaria onset >2 months after returning from travel 
(3,4). Late occurrence of infection could have severe con-
sequences if physicians do not relate symptoms suggestive 
of malaria to travel history. Another risk is transfusion-
transmitted malaria from an asymptomatic carrier of P. fal-
ciparum trophozoites (5).
Cases of late occurrence of P. falciparum malaria have 
been reported (6–9), but risk factors are unknown. The ob-
jective of this study was to determine the incidence and 
identify factors associated with prolonged P. falciparum 
infection in immigrant travelers.
The Study
A case–control study was conducted among patients 
with  P.  falciparum malaria diagnosed at Bichat-Claude 
Bernard and Saint-Denis Hospitals in Paris, France. Many 
African immigrants come to these hospitals. Participants 
traveled to or lived in an area endemic for malaria and had a 
P. falciparum infection during 1996–2005. The diagnostic 
criterion was P. falciparum trophozoites on a blood smear 
conﬁ  rmed by the Centre National de Reference du Palu-
disme (CNRP) in Paris, without epidemiologic evidence 
of autochthonous, transfusion-transmitted, or occupational 
malaria. Case-patients had P. falciparum infections detect-
ed >59 days after their arrival in France. Controls had P. 
falciparum infections detected <30 days after their arrival. 
For each case-patient, 4 controls were matched by calendar 
year and hospital of diagnosis (70 cases and 280 controls). 
Data were collected from the CNRP database in which all 
cases are prospectively included and medical records are 
checked. We only considered immigrants (persons born in 
an area endemic for malaria and residing in France), which 
resulted in 61 case-patients and 197 controls. We distin-
guished ﬁ  rst-arrival immigrants (persons who emigrated to 
France and never returned to areas endemic for malaria) 
from visiting friends and immigrant relatives (persons who 
traveled back to areas endemic for malaria after immigra-
tion to France). 
Logistic regression was used to identify factors associ-
ated with prolonged P. falciparum infection and estimate 
odds ratios (ORs) and 95% conﬁ  dence intervals (CIs). For 
multivariate analysis, variables with p values <0.25 were 
introduced into the model and removed after a backward 
stepwise approach, which resulted in only values with 
p<0.05 in the ﬁ  nal model (except for age groups). Statisti-
cal analysis was performed by using Stata software version 
8.2 (Stata Corporation, College Station, TX, USA).
During the 10-year period, 61 (2.3%) late infections 
occurred among 2,680 diagnosed P. falciparum malaria in-
fections. The median diagnosis delay was 5 months (inter-
quartile range 3–9 months). These infections included 10 
patients (5 pregnant women, 2 HIV-positive patients, and 3 
ﬁ  rst-arrival immigrants) with clinical malaria >1 year after 
their arrival. Four of them, all pregnant women, had clini-
cal malaria >3 years after their arrival. For the case–control 
study, 197 controls were compared with 61 case-patients 
(Figure). Table 1 shows the main characteristics of case-
patients and controls. Case-patients were younger (median 
age 30.6 years vs. 34.5 years, p = 0.04) and more often fe-
male (54.1% vs. 38.1%, p = 0.03) than controls. The mean 
parasitemia level was lower for case-patients than for con-
trols (0.6% vs. 1.4%, p = 0.04), including patients with 8 
asymptomatic cases versus none of the controls (in these 
cases, diagnosis of malaria was made through systematic 
checking). 
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Island, FranceAmong immigrant travelers, 3 groups had a higher risk 
for prolonged P. falciparum infection: pregnant women, 
ﬁ  rst-arrival immigrants, and HIV-positive patients. A total 
of 27.9% (n = 17) of the patients were pregnant women, 
with a median (range) age of 22 (16–36) years. All were 
of African origin and had become pregnant in France; 10 
(58.8%) were in their second trimester, 5 (29.4%) were in 
their third trimester. First-arrival immigrants were younger 
than other patients (mean age 26.2 vs. 37.6 years, p = 0.001). 
All patients were of African origin except for 1 Indian man. 
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Table 1. Univariate analysis of factors associated with prolonged Plasmodium falciparum infection in 248 immigrant travelers* 
Variable Case-patients (n = 61), no. (%)  Controls (n = 197), no. (%)  OR (95% CI)  p value 
Sex 
  Female  33 (54.1)  75 (38.1)  1
  Male  28 (45.9)  122 (61.9)  0.52 (0.29–0.93)  0.03
Age, y 
  <5  2 (3.3)  10 (5.1)  1
  5–14  5 (8.2)  18 (9.1)  1.39 (0.22–8.51) 
  15–60  53 (86.9)  163 (82.7)  1.63 (0.34–7.66)  0.83
  >60  1 (1.6)  6 (3.1)  0.83 (0.06–11.23) 
Origin 
  Sub-Saharan Africa  55 (90.2)  181 (91.9)  1
  Comoros Islands  5 (8.2)  14 (7.1)  1.18 (0.41–3.41) 
  Other  1 (1.6)  2 (1)  1.65 (0.15–18.5)  0.89
  South America  0 1 (0.5)  NA
 Caribbean  0 1  (0.5)  NA
 India  1  (1.6)  0 NA
First-arrival immigrant 
  No  24 (39.3)  183 (92.9)  1
  Yes  37 (60.7)  14 (7.1)  20.15 (9.54–42.57)  <0.001
Region of malaria acquisition 
  West Africa  32 (52.5)  132 (67)  1
  Central Africa  22 (36.1)  44 (22.3)  2.06 (1.09–3.92)  0.03
  East Africa  1 (1.6)  2 (1)  2.06 (0.18–23.46) 
  Comoros Islands  5 (8.2)  18 (9.1)  1.15 (0.4–3.32) 
  Other  1 (1.6)  1 (0.5)  4.12 (0.25–67.74) 
Chemoprophylaxis 
  No  50 (82)  118 (59.9)  1
  Yes  9 (14.8)  71 (36)  0.3 (0.14–0.65)  0.002
  Unknown   2 (3.2)  8 (4.1)  NA
Prophylaxis with mefloquine 
  No  56 (91.8)  186 (94.4)  1
  Yes  3 (4.9)  3 (1.5)  3.32 (0.65–16.92)  0.15
  Unknown  2 (3.3)  8 (4.1)  NA
Antimalarial self-medication 
  No  55 (90.2)  171 (86.8)  1
  Yes  5 (8.2)  15 (7.6)  1.04 (0.36–2.98)  0.95
  Unknown   1 (1.6)  11 (5.6)  NA
  Men  28 (45.9)  122 (61.9)  1
  Nonpregnant women  16 (26.2)  69 (35)  1.01 (0.51–2) 
  Pregnant women  17 (27.9)  6 (3.1)  12.35 (4.46–34.14)  <0.001
HIV status 
  Negative  22 (36.1)  42 (21.3)  1
  Positive  12 (19.7)  6 (3.1)  3.82 (1.26–11.56)  0.02
  Unknown  27 (44.3)  149 (75.6)  NA
Symptomatic malaria 
  No  8 (13.1)  0 (0)  1
  Yes  53 (86.9)  197 (100)  0.3 (0.25–0.47)  <0.001
Parasitemia†
  High   2 (3.3)  18 (9.1)  1
  Low  59 (96.7)  179 (90.9)  1.61 (0.53–4.9)  0.4
*OR, odds ratio; CI, confidence interval; NA, not applicable. 
†Parasitemia (parasitized erythrocytes) was considered high if >4% and low if <4% by World Health Organization criteria. P. falciparum Infection in Immigrants, Paris
HIV infection was associated with prolonged infection, but 
HIV status was not introduced into the ﬁ  nal model because 
of missing data. Although chemoprophylaxis with chlo-
roquine-proguanil was less common among case-patients 
than controls (8.5% vs. 21.2%, p = 0.03), the reverse was 
seen, although not signiﬁ  cantly, with meﬂ  oquine use (4.9% 
vs. 1.5%, p = 0.15). Multivariate analysis (Table 2) showed 
that factors positively and independently associated with 
prolonged  P.  falciparum infection in immigrant travel-
ers were being a ﬁ  rst-arrival immigrant (OR 22.93, 95% 
CI  9.74–53.96, p<0.001), being a pregnant woman (OR 
4.21, 95% CI 1.13–15.77, p = 0.03), and meﬂ  oquine pro-
phylaxis (OR 11.55, 95% CI 2.06–64.78, p<0.005).
We also observed cases of malaria in a 26-year-old 
Caucasian man and a 2-year-old African girl who were hos-
pitalized with diagnosis delays of 221 days and 127 days, 
respectively. The man was a French expatriate who lived 
in Madagascar for 2 years and took regular chloroquine-
proguanil prophylaxis. He was hospitalized 7 months af-
ter his return with severe P. falciparum malaria (impaired 
consciousness) and responded to treatment. The girl had 
traveled in Mali for 2 weeks and took regular chloroquine-
proguanil prophylaxis. She was hospitalized 4 months after 
her return with uncomplicated P. falciparum malaria oc-
curring concomitantly with a Salmonella spp. infection that 
had been treated 1 week earlier with ceftriaxone.
Conclusions
Three independent factors were positively associated 
with prolonged P. falciparum infection: being a ﬁ  rst-arrival 
immigrant, being a pregnant woman, and taking meﬂ  oquine 
prophylaxis. The ﬁ  rst 2 factors most likely reﬂ  ect partial 
control of parasitemia by acquired immunity. Persons liv-
ing in areas with high transmission of malaria acquire this 
immunity during childhood. In these areas, P. falciparum 
infections in adults are mostly asymptomatic with transient 
low parasitemia levels (10). Chronic asymptomatic car-
riage of P. falciparum helps prevent symptomatic malaria 
attacks (11). In a previous study, 29% of asymptomatic Li-
berian children had detectable P. falciparum 4 weeks after 
immigration to the United States (Minnesota) (12). We pos-
tulate that many ﬁ  rst-arrival immigrants are asymptomatic 
P. falciparum carriers upon their arrival in France. Their 
immunity probably prevents clinical symptoms for a few 
months, but in the absence of reinfections their immunity 
would decrease and symptoms would occur. In some cases, 
P. falciparum infections may not be the cause of illness 
when patients come to a hospital. 
Several immunologic mechanisms have been suggest-
ed to explain late manifestations of P. falciparum malaria 
in pregnant women. A decrease in immunity during preg-
nancy could be one explanation (10). Other authors have 
suggested that antigenic variability could be responsible 
for impaired control of parasitemia (13). The role of me-
ﬂ  oquine prophylaxis in delayed onset of malaria has been 
suggested (14). We found a positive association between 
meﬂ  oquine use and prolonged P. falciparum infection, but 
this drug was seldom used by our study group. This associ-
ation is probably caused by the long half-life of meﬂ  oquine 
(>3 weeks).
This study also highlights the risk for blood transfu-
sion–transmitted malaria, a rare but serious complication. 
Mungai et al. (15) reported 32 cases of transfusion-trans-
mitted P. falciparum malaria in the United States during 
1963–1999 (mortality rate 18.8%). Current US guidelines 
recommend obtaining a thorough travel history and defer-
ring blood donation if potential donors have emigrated 
from areas endemic for malaria in the preceding 3 years. 
However, this measure may not prevent transmission if P. 
falciparum is present for >3 years (as in 4 pregnant women 
in our study). In France, systematic serologic analysis for 
Plasmodium spp. in blood donors born in areas endemic for 
malaria was implemented in 2002 (5).
Our ﬁ  ndings suggest that physicians should consider 
the risk for prolonged P. falciparum infection in immigrant 
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Figure. Delay in days or years between arrival in France and 
diagnosis of imported Plasmodium falciparum malaria, Bichat-
Claude Bernard Hospital and Saint Denis Hospital, Paris, France, 
1996–2005.
Table 2. Factors independently associated with prolonged 
Plasmodium falciparum infection in 248 immigrant travelers* 
Variable OR (95% CI)*  p value
Age, y 
<5 1
5–14 1.45 (0.15–13.74) 
15–60 1.72 (0.25–12) 
>60 3.04 (0.16–56.25) 0.45
First-arrival immigrant 
No 1
Yes  22.93 (9.74–53.96)  <0.001
Men 1
Nonpregnant women  0.67 (0.28–1.59) 
Pregnant women  4.21 (1.13–15.77)  0.03
Use mefloquine
No 1
Yes  11.55 (2.06–64.78)  0.005
*OR, odds ratio; CI, confidence interval. pregnant women and ﬁ  rst-arrival immigrants even without 
recent travel to a country endemic for malaria. The prev-
alence of asymptomatic P. falciparum carriers in France 
or other northern countries is unknown but could be high 
with the increase in immigration. Public health authori-
ties should be aware of the risk these persons represent for 
blood donations. 
Acknowledgments
We thank Michel Cot, Pascal Ringwald, and Tania Ikowsky 
for critically reading the manuscript.
Dr D’Ortenzio is a physician and epidemiologist at the Insti-
tut de Veille Sanitaire, Cellule Inter-Régionale d’Epidémiologie 
Réunion-Mayotte on Réunion Island. His primary research inter-
ests include clinical and epidemiologic aspects of malaria, arbovi-
rus epidemiology, and travel medicine.
References
  1.   World Health Organization. International travel and health. Geneva: 
The Organization. 2005 [cited 2007 Oct 25]. Available from http://
whqlibdoc.who.int/publications/2005/9241580364_chap7.pdf
  2.   Legros F, Arnaud A, El Mimouni B, Danis M. Paludisme d’importation 
en France métropolitaine: données épidémiologiques 2001–2004. 
Bulletin Epidémiologique Hebdomadaire. 2006;32:235–6.
  3.   Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of 
malaria⎯implications for chemoprophylaxis in travelers. N Engl J 
Med. 2003;349:1510–6.
  4.   Williams HA, Roberts J, Kachur SP, Barber AM, Barat LM, Bloland 
PB, et al. Malaria surveillance—United States, 1995. MMWR CDC 
Surveill Summ. 1999;48:1–23.
    5.   Bruneel F, Thellier M, Eloy O, Mazier D, Boulard G, Danis 
M, et al. Transfusion-transmitted malaria. Intensive Care Med. 
2004;30:1851–2.
  6.   Cristau P, Desbaumes J, Giraud D. Late manifestations of Plas-
modium falciparum after leaving an endemic area. Presse Med. 
1987;16:493.
  7.   Revel MP, Datry A, Saint Raimond A, Lenoir G, Danis M, Gentilini 
M. Plasmodium falciparum malaria after three years in a non-en-
demic area. Trans R Soc Trop Med Hyg. 1988;82:832.
  8.   Krajden S, Panisko DM, Tobe B, Yang J, Keystone JS. Prolonged 
infection with Plasmodium falciparum in a semi-immune patient. 
Trans R Soc Trop Med Hyg. 1991;85:731–2.
  9.   Giobbia M, Tonon E, Zanatta A, Cesaris L, Vaglia A, Bisofﬁ   Z. Late 
recrudescence of Plasmodium falciparum malaria in a pregnant 
woman: a case report. Int J Infect Dis. 2005;9:234–5.
10.   Hviid L. Naturally acquired immunity to Plasmodium falciparum 
malaria in Africa. Acta Trop. 2005;95:270–5.
11.   Druilhe P, Pérignon JL. A hypothesis about the chronicity of malaria 
infection. Parasitol Today. 1997;13:353–7.
12.    Maroushek SR, Aguilar EF, Stauffer W, Abd-Alla MD. Malaria 
among refugee children at arrival in the United States. Pediatr Infect 
Dis J. 2005;24:450–2.
13.   Staalsoe T, Hviid L. The role of variant-speciﬁ  c immunity in asymp-
tomatic malaria infection: maintaining a ﬁ  ne balance. Parasitol To-
day. 1998;14:177–8.
14.   Day JH, Behrens RH. Delay in onset of malaria with meﬂ  oquine 
prophylaxis. Lancet. 1995;345:398.
15.   Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-
transmitted malaria in the United States from 1963 through 1999. N 
Engl J Med. 2001;344:1973–8.
Address for correspondence: Eric D’Ortenzio, Cellule Inter-Régionale 
d’Épidémiologie Réunion/Mayotte, Institut de Veille Sanitaire, 2 Bis Ave 
Georges Brassens, BP 50, 97408 Saint-Denis, Cedex 9, Réunion Island, 
France; email: ericdortenzio@gmail.com




[kan′-di-də], from the Latin—candidus (glowing white)
A genus of yeastlike Fungi Imperfecti (for which no sexual reproductive stage is known) of the family 
Cryptococcaceae that produce yeast cells, mycelia, pseudomycelia, and blastospores. When grown in 
the laboratory, Candida appears as large, round, white or cream colonies on agar plates. C. albicans 
infection (or thrush) features distinctive white mouth lesions; “albicans” means becoming white. 
C. dubliniensis, ﬁ  rst identiﬁ  ed in 1995 at the University of Dublin, is an opportunistic pathogen that 
can cause both superﬁ  cial and invasive infections, particularly in the immunocompromised.
Source: Dorland’s illustrated medical dictionary. 30th ed. Philadelphia: Saunders; 2003; Sullivan, DJ, Westerneng TJ, Haynes KA, 
Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterisation of a novel species associated 
with oral candidosis in HIV-infected individuals. Microbiology 1995;141:1507–121. 